Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Breast Cancer Res Treat ; 188(1): 65-75, 2021 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-34091830

RESUMEN

BACKGROUND: Cell spheroids and aggregates generated from three-dimensional (3D) cell culture methods are similar to in vivo tumors in terms of tissue morphology, biology, and gene expression, unlike cells grown in 2D cell cultures. Breast cancer heterogeneity is one of the main drug resistant mechanisms and needs to be overcome in order to increase the efficacy of drug activity in its treatments. METHODS: We performed a unique 3D cell culture and drug efficacy study with trastuzumab emtansine (Kadcyla®, T-DM1) across five breast cancer cell lines (BT-474, SK-BR-3, MDA-MB-361, MDA-MB-175, and MCF-7) that were previously investigated in 2D cell culture. We performed HER2 IHC staining, cell viability experiments, Gene-protein-assay (GPA), and T-DM1 internalization studies. RESULTS: We obtained significantly different results including higher IC50 for some of the cell lines. Our GPA showed some significant heterogeneous HER2 gene and protein expression in 3D cultured spheroids or aggregates. The fluorescent images also showed that a longer incubation time is needed for T-DM1 to be internalized effectively into 3D cultured spheroids or aggregates. CONCLUSION: Our study demonstrated that the difference of T-DM1 drug activity in 3D spheroids or aggregates might be due to tumor heterogeneity and less efficient internalization of T-DM1 that is not seen using 2D cell culture models. Drug studies using 3D cell culture are expected to provide biologically relevant models for determining drug activity in tumor tissue in future drug response and resistance research.


Asunto(s)
Neoplasias de la Mama , Maitansina , Ado-Trastuzumab Emtansina , Técnicas de Cultivo de Célula , Línea Celular Tumoral , Femenino , Humanos , Receptor ErbB-2 , Trastuzumab
3.
Am J Clin Pathol ; 139(2): 242-54, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23355209

RESUMEN

Abnormalities of the MYC oncogene on chromosome 8 are characteristic of Burkitt lymphoma and other aggressive B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). We recently described a colorimetric in situ hybridization (CISH) method for detecting extra copies of the MYC gene in DLBCL and the frequent occurrence of excess copies of discrete MYC signals in the context of diploidy or polyploidy of chromosome 8, which correlated with increased mRNA signals. We further observed enlarged MYC signals, which were counted as a single gene copy but, by their dimension and unusual shape, likely consisted of "clusters" of MYC genes. In this study, we sought to further characterize these clusters of MYC signals by determining whether the presence of these correlated with other genetic features, mRNA levels, protein, and overall survival. We found that MYC clusters correlated with an abnormal MYC locus and with increased mRNA. MYC mRNA correlated with protein levels, and both increased mRNA and protein correlated with poorer overall survival. MYC clusters were seen in both the germinal center and activated B-cell subtypes of DLBCL. Clusters of MYC signals may be an underappreciated, but clinically important, feature of aggressive B-cell lymphomas with potential prognostic and therapeutic relevance.


Asunto(s)
Genes myc , Linfoma de Células B Grandes Difuso/genética , Familia de Multigenes , Proteínas Proto-Oncogénicas c-myc/genética , ARN Mensajero/genética , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Colorimetría , Ciclofosfamida/uso terapéutico , ADN de Neoplasias/análisis , Doxorrubicina/uso terapéutico , Dosificación de Gen , Humanos , Hibridación in Situ/métodos , Hibridación Fluorescente in Situ , Ganglios Linfáticos/metabolismo , Ganglios Linfáticos/patología , Linfoma de Células B Grandes Difuso/tratamiento farmacológico , Linfoma de Células B Grandes Difuso/mortalidad , Linfoma de Células B Grandes Difuso/patología , Prednisona/uso terapéutico , Proteínas Proto-Oncogénicas c-myc/metabolismo , Transducción de Señal , Tasa de Supervivencia , Análisis de Matrices Tisulares , Translocación Genética , Vincristina/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA